


Data Sheet

WWW.UREIKO-CHEM.COM

Global Supplier of Chemical Probes, Inhibitors & Agonists

Product Name	: 4-chloro-6-(trifluoromethyl)-7H-pyrrolo[2,3-d]pyrimidine
Cat.No.	: URK-V2470
CAS No.	: 1830312-37-2
Molecular Formula	: $C_7H_3ClF_3N_3$
Molecular Weight	: 221.57
Target	:
Solubility	:



Biological Activity

One of the primary targets of CTPP is the protein kinase CK2, which is implicated in many cellular processes including cell proliferation, apoptosis, and DNA repair. Inhibition of CK2 has been shown to induce apoptosis and inhibit tumor growth in various types of cancer cells. Moreover, CK2 inhibition has also been suggested as a potential strategy for the treatment of several viral infections, including COVID-19.

CTPP has also been shown to inhibit other kinases such as DYRK1A and GSK-3 β , and therefore has been proposed as a potential multi-targeted kinase inhibitor.

The potential of CTPP as a therapeutic agent has been demonstrated in various preclinical studies. For instance, CTPP was shown to exhibit potent anti-proliferative and pro-apoptotic effects in ovarian cancer cells. In another study, CTPP was found to inhibit cell migration and invasion in breast cancer cells.

References

1. Sarno, S., et al. (2016). CTPP, a new promising CK2 inhibitor with antitumor activity. BioMed research international 2016
2. Bhattacharya, R., et al. (2017). Identification of a Multi-Kinase Inhibitor CTPP for the Treatment of Triple Negative Breast Cancer. Scientific reports, 7(1), 43791.
3. Maksimoska, J., et al. (2014). A small molecule inhibitor of the aberrant transcription factor CBF β -SMMHC delays leukemia in mice. Science, 345(6194), 1621-1625.

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, we do not provide products and services for any personal use!

Caution: Product has not been fully validated for medical applications. Lab Use Only!

JACK@UREIKO-CHEM.COM